INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial disorder determined not only by genetic but also environmental and risk factors. Overall, the most important pathogenetic mechanisms causing the development of the AMD are the formation of drusen, hypoxia, local inflammation, which might cause neovascularization. The blockage of the neovas-cularization chain has been considered to inhibit the development of AMD. The neovascularization is mainly induced by retinal hypoxia. Tissue ischemia leads to an increased secretion of the vascular endothelial growth factor (VEGF) and higher expression of the VEGF receptor 2. VEGF causes vasodilatation increasing vascular permeability and protease activity. Such changes allow for the development and expansion of vascular network in the surrounding tissues and its remodeling (Svagzdys et al., 2007; Liutkeviciene et al., 2010) . The fragmentation of basilar membrane and intracellular connective tissue is essential for the formation of new capillaries. Activated endothelial cells release various matrix metalloproteinases (MMPs) which degrading the basilar membrane allow capillaries to grow beneath the retina and between retinal layers. MMPs, which are found in all organisms, are endopeptidases that contain an active site Zn 2+ and are divided into subfamilies or clans based on evolutionary relationships and structure of the catalytic domain. MMPs comprise a family of currently 25 related, yet distinct vertebrate gene products, of which 24 are found in mammals (Vihinen et In this article we focus on an impact of mutation on MMP-2, -3 and -9 activity regulation and influence on AMD development.
Structure, activity and mutation impact on activity regulation of matrix metalloproteinases (MMP-2, MMP-3 and MMP-9) Structure of all known MMPs is similar (Figure) . sp -signal sequence; pro -pro-domain; cat -catalytic domain, FNII -fibronectin type II motif; L1 -linker 1; Hpx -hemopexin domain; L2 -linker 2; Mb -plasma membrane; TM -transmembrane domain; Cy -cytoplasmic tail; CysR -cysteine rich; Ig -immunoglobulin domain; GPI -glycosylphosphatidilyinositol anchor7 quired during development and normal physiology in four ways: 1) MMPs may affect cell migration by changing the cells from an adhesive to nonadhesive phenotype and by degrading the ECM; 2) MMPs may alter ECM microenvironment leading to cell proliferation, apoptosis, or morphogenesis; 3) MMPs may modulate the activity of biologically active molecules such as growth factors or growth factor receptors by cleaving them or releasing them from the ECM; 4) MMPs may alter the balance of protease activity by cleaving the enzymes or their inhibitors (Westermarck et al., 1999) .
Activation of MMPs expression could be caused by various gene polymorphisms in promoter region, when a binding place of transcriptor factors or other regulating ele ments is disrupted. MMP polymorphisms can be caused by nucleotide changes within promoter region by insertions, substitutions or microsatellite instability (Ye, 2000) . In around 90% of cases a single nucleotide polymorphism is determined where one of the basic changes appear in DNA strain (Ra et al., 2007) . However, several allele polymorphims can be determined in MMP gene promoter regions. Most parts of detected polymorphisms are not biologically active. Only a small part of polymorphisms which changes gene transcription intensity is biologically active, therefore, they may have an impact on genetic predisposition to certain disease (Ye, 2000) . A common variant in the promoter region of the human matrix metalloproteinase-3 (MMP-3) gene with 1 allele having a run of 5 adenines (5A) and the other having 6 adenines (6A) has an impact on gene expression. MMP-3 gene is located in chromosome 11 11q22.2-11q22.3 region. Insertion of one adenine (A) in -1171 base-pair position of MMP-3 promoter causes 6 adenines (6A) formation instead of 5 adenines (5A). It was shown that 6A allele has a higher bind ing affinity to ZBP-89 transcription factor, which decreases promoter transcription activity and certain gene expression (Ye et al., 1998) . In vitro methods showed that 5A allele has a high er activity and effect on gene expression compared to 6A allele (Medley et al., 2003) . Ex vivo method showed that MMP-3 mRNA and protein activity depends on genotype: 5A/5A shows the highest activity, 5A/6A -the middle activity and the lowest activity shows 6A/6A genotype (Ye et al., 1998; Medley et al., 2003) . A mutation (NCBI SNP identification no. rs2285053) which causes an increase in promoter activity was determined in the MMP-2 (-735) gene promoter transcription re gion. MMP-2 gene is located in 16q13-q21 region. The C to T allelic variation located at nucleotide -735 disrupts the Sp1-binding site in pro moter region and significantly leads to a low trans criptional activity, therefore T allele has a markedly lower promoter activity than the C allele (Yu et al., 2004 ). In addition, another C to T allelic variation located in MMP-2 at nucleotide -1306 (NCBI SNP identification no. rs243865) disrupts the SP1-binding site of transcription factor in promoter region. It is a simmilar effect as it happens for MMP-2 (-735) gene promoter transcription region mutation (Vasků et al., 2002) , where promoter loses 50% activity (Price et al., 2001) . A transition of C to T at the 1562 base-pair position upstream of the transcription initiation site (-1562 C/T) of MMP-9 (NCBI SNP identification No. rs3918242) was shown to have an effect on promoter activity. Transition of C nucleotide to T nucleotide causes more difficulties for nucleic protein complex bind to DNA strain in the presence of T allele. It was determined that once C allele mutates to T allele, a promoter activity increases 1.5 times (Zhang et al., 1999) . MMP-9 gene is located in 20q11.2-q13.1 region. Matrix metalloproteinases are involved in vascular remodeling, and these appear to be active agents degrading extracellular matrix proteins. Their expression on transcription level depends on gene promoter mutations and various transcription factors.
Expression of matrix metalloproteinases in hu man retina and choroid
Bruch's membrane is a pentalaminated extracellular matrix allowing bidirectional diffusion pathways between the retinal pigment epithelium and the choroidal blood supply. Aging is associated with progressive thickening due to deposition of matrix components and membranous debris rich in lipids. A consequence of the aging process is an exponential decline in the hydraulic conductivity of Bruch's memb rane (Hogan, 1972) . Hematoretinal barrier might be disrupted only when a lession in Bruch's membrane or in retinal pigment epithelium occurs. Li et al. found that MMP-3, and MMP-2 and -9 were present in human Bruch's membrane, and that the level of the two inactive gelatinases increased with the age of the donor (Li et al., 1999) . Regional diff erences were apparent in the levels of the two gelatinases. The level of MMP-9 remained invariant, while MMP-2 was lower in the macular region than in the periphery (Li et al., 1999) . Given that the thickness of Bruch's membrane increases with age and that of choroid decreases, the observed increase in MMP levels is likely to occur mainly in Bruch's membrane. Cultured retinal pigment epithelium (RPE) cells have been reported to synthesize and secrete MMP-1, -2, -3, and -9 and TIMPs as well. The origin of the various MMPs found in Bruch's membrane and choroid remains unknown. The three potential sources are: 1) RPE cells, 2) choroidal cells, and 3) plasma in the choroidal vessels (Ruiz et al., 1996; Della et al., 1996) .
There are two pathways whereby these en zymes may be incorporated into Bruch's membrane. First, the enzymes may be released from plasma, RPE, and / or choroidal cells and then diffuse into Bruch's membrane. This is certainly a possibility for the smaller molecular weight forms such as MMP-1 (52 kDa), MMP-2 (65 kDa), and MMP-3 (57 kDa), because the molecular weight exclusion limit for Bruch's membrane is approximately 65 to 75 kDa. Second, release of MMPs may be coincident with the synthesis of structural components of Bruch's membrane and, therefore may be incorporated passively into the ECM of Bruch's membrane. Such a pathway would allow an incorporation of higher molecular weight enzymes such as MMP-9 (Hussain et al., 1999).
MMP-1, MMP-2, MMP-3, and MMP-9 exp ression is regulated by various ways such as transcription level, activation of latent MMPs, and inhibition of MMP activity by tissue inhibitors of metalloproteinases (TIMPs) (Chakraborti et al., 2003) . TIMPs are known as natural tissue inhibitors, which regulate active and non-active balance of MMP forms. MMPs are initially expressed in an enzymatically inactive state due to the interaction of a cysteine residue of the pro-domain with the zinc ion of the catalytic site. Only after disruption of this interaction by a mechanism called cysteine switch, which is usually mediated by proteolytic removal of the pro-domain or chemical modification of the cysteine residue, the enzyme becomes proteolytically active. Choroidal neovascularization (CNV) is associated with an up-regulation of MMP-9 at the transcriptional level and an activation of pro-MMP-2 by MT1-MMP. This process might be blocked by physiological / natural (TIMP-1 and TIMP-2) and also synthetic inhibitors (Lambert et al., 2003) .
MMPs are thought to play a key role during the early phases of choroidal neovascularization. The synthetic inhibitor interacting preferentially with MMP-2, MMP-9, and MT1-MMP (MMP-14) is more efficient comparing to a broad-spectrum synthetic inhibitor in a case of cho roidal neovascularisation. MMPs might have contrary functions -induce or block choroidal neovascularisation development (Lambert et al., 2003). (27) . No significant differences in either genotype distribution or allelic frequencies of MMP2 (-1306C>T) were found among the patients with dry AMD, wet AMD and control group (Ortak et al., 2013 ). An allele of MMP-2 rs2287074 was less prevalent in subjects with late AMD than in those with early or no AMD (p = 0.01) (Seitzman et al., 2008) . The third study also proved that analysis of MMP-2 (-1306 C/T) gene polymorphism has not revealed any differences in the genotype distribution between patients with early AMD and reference group subjects when analyzed in overall group, but MMP-2 gene C/C genotype was more frequent in AMD patients younger than 65 years comparing to AMD group ≥65 years (67.21% vs. 49.37%, p = 0.039), and C/T genotype was more frequent in AMD patients ≥65 years comparing to AMD patients <65 years (26.23% vs. 44.3%, p = 0.033) (Liutkeviciene et al., 2013) . MMP-2 expression in experimental models (Berglin et al., 2003) and in Bruch's membrane-choroid prepara tions in human donor eyes with AMD diagnosis were also analyzed (Hussain et ., 1998) . The study analysing MMP-3 gene polymorphism on agerelated macular degeneration development in patients with myocardial infarction was car ried out as well (Liutkevičienė et al., 2012) . The study results revealed that MMP-3 gene polymorphism did not have any predominant effect on the development of AMD in patients with myocardial infarction (Liutkeviciene et al., 2012) . German study showed that MMP-3 expression in the retinal pigment epithelium was induced by oxidative stress (Alge-Priglinger et al., 2009). It is known that oxidative stress is one of the risk factors for the development of AMD, and it is possible that MMP-3 might affect the development of AMD in this way (Liutkeviciene et al., 2012) . Swedish researchers conducted a study where the expression of several MMPs, including MMP-3, was analyzed, but no data suggesting MMP-3 involvement in the development of AMD were found (Liutkevičienė et al., 2012) .
Matrix metalloproteinases (MMP-2, -3 and -9) association with age-related macular degeneration
The studies analyzing an association between MMP-9 and AMD are inconsistent as well. In a few studies, a reduction in MMP-9 was found in choroidal neovascular membranes (Lambert et al., 2002) and in serum (Zeng et al., 2012) , while other studies showed an increase in MMP-9 in the aqueous humor (Jonas et al., 2012) , plasma (Chau et al., 2007) , and choroidal neovascular membranes (Zeng et al., 2004) . To our knowledge, only one study done by Fiotti et al. revealed the influence of the MMP-9 genotype, which causes greater gene expression on AMD (Zeng et al., 2004) . This study found a relationship between the length of MMP-9 gene promoter microsatellites and choroidal neovascularization in AMD patients (Fiotti et al., 2007) . It has been determined that carriers of one allele with 22 repeats have more than double the risk of AMD. This polymorphism does not cause the disease but increases the MMP-9 expression leading to increased vascular permeability and choroidal neovascularization (Fiotti et al., 2007) . No difference between the major AMD risk factors (gender, age, diabetes mellitus, cigarette smoking, and dyslipidemia) and MMP-9 polymorphism was found. The logistic regression analysis showed that the status of carrier of a microsatellite 22 repeats was the only variable entering into the equation (P = 0.011). The single association was high body mass index value which is linked to a higher risk of developing AMD (Fiotti et al., 2007) . The number of cytosine-adenine (CA) sequences in the MMP-9 gene promoter region was found to determine the transcription activity (Ye, 2000) . Studies with mice mesangial cells have shown that 24 repeats of CA sequences in the MMP-9 gene promoter region result in up to 20 times higher MMP-9 expression compared with 20 repeats of CA sequence (Fornoni et al., 2002) . Furthermore, the results of the study by Steen found opposite results and proved that the mean plasma levels of MMP-2 were not significantly different in the three groups but the mean plasma MMP-9 levels were significantly higher in AMD and CNV groups compared to that of the control group (265 ± 134 ng/mL, 659 ± 315 ng/mL, and 740 ± 494 ng/mL (p = 0.008)) (Chau et al., 2007) . To our knowledge, there is only one study analyzing the impact of MMP-2, MMP-3, and MMP-9 genes polymorphism on the development of early AMD. This study proved that the frequency of the MMP-2 (-735) C/T and MMP-3 (-1171) 5A/6A genotypes did not differ significantly between the patients with early AMD and the control group, while the MMP-9 (-1562) C/C genotype was more frequently detected in patients with AMD than the control group (73.7% vs. 64.6%, P = 0.048) (Liutkeviciene et al., 2013) . The logistic regression analysis showed that the MMP-9 (-1562) C/C genotype increased the likelihood to develop early AMD (OR = 1.51, 95% CI: 1.01-2.21; P = 0.046). After the subdivision into the groups by age, a significant difference only in the frequency of the MMP-9 (-1562) C/C genotype was found comparing the AMD patients and the control group younger than 65 years (79.7% vs. 66.4%, P = 0.039) (Liutkeviciene et al., 2013).
CONCLUSIONS
Age-related macular degeneration is a multifactorial disorder. Alteration of matrix metalloproteinases plays a very important role in AMD pathogenesis, especially in the early phases of choroidal neovascularization. During pathological process MMP-2, MMP-3 and MMP-9 present in human Bruch's membrane and RPE at different level and position are involved in inflammatory process. MMP-2, MMP-3, and MMP-9 expression are regulated by various ways: as a transcription, activation of latent MMPs, and inhibition of MMP activity by tissue inhibitors of metalloproteinases. However, MMP-2, MMP-3 and MMP-9 action facts in AMD pathogenesis are still controversial therefore further research is necessary.
remodeliacijoje užląstelinės angiogenezės metu, o tai -pagrindinis patologinis procesas, susijęs su amžinės geltonosios dėmės degeneracijos reiškiniais. Aktyvuotos endotelio ląstelės atpalaiduoja matrikso metalo proteinazes, kurios, ardydamos bazinę ląs-telės membraną, sudaro sąlygas kapiliarams įaugti po tinklaine ir tarp tinklainės sluoksnių. Iš tokių krau jagyslių dažnai kraujuoja, jų sienelės praleidžia skysčius, auga fibrozinis audinys, tinklainė pa burksta, blogėja regėjimas.
Šiame straipsnyje aptariame mutacijų poveikį MMP-2, MMP-3 ir MMP-9 genų aktyvumo reguliacijai ir poveikį AGDD reiškiniams.
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